Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Aïda Amer/Axios

Recent data suggests that Moderna's coronavirus vaccine may maintain a higher effectiveness over time than Pfizer's.

Why it matters: The effectiveness gap could always disappear with more data, and both vaccines remain very effective against severe disease. But if the gap does hold up, it raises questions about whether the two vaccines should be treated the same way policy-wise.

Driving the news: Several studies — both preprints and those that have been peer-reviewed — have found a difference between the two vaccines' effectiveness over time, although some experts have cautioned that this could stem from flawed head-to-head comparisons.

  • The studies have evaluated different measures of effectiveness, but all have found that effectiveness against severe disease remains relatively high.
  • "There have been sort of signals from enough separate sources that start to paint a picture that may reflect a real biological phenomenon — a real difference. I’m starting to believe that there’s something underlying it," said Natalie Dean, an Emory professor who specializes in vaccine study design.

Zoom in: In a study released last week, the CDC found that Moderna was significantly more effective against hospitalizations and emergency department or urgent care encounters than the Pfizer or J&J vaccines.

  • A second smaller study found more similar effectiveness level against hospitalization between the two mRNA vaccines.

Between the lines: Pfizer was the first vaccine authorized for use in the U.S. and began being administered several weeks before the Moderna vaccine.

  • "Because of the way the rollouts happened, the oldest and most vulnerable and sickest people, like nursing home residents, got Pfizer," said Cornell virologist John Moore.
  • That means it's possible that some of the effectiveness gap showing up in some studies is a result of Pfizer being administered earlier and in more vulnerable populations.
  • However, the large CDC study that found a significant difference in the vaccines' effectiveness found that Moderna's was higher across all ages.

Possible reasons for the difference include that Moderna has a much higher dosing regimen than Pfizer, and the second shot is given after a slightly longer interval.

  • And, while the vaccines are both made using mRNA technology, they have structural differences.

Yes, but: Both vaccines are nearly equal in their capacity to "do what a vaccine needs to do, which is protect against severe illness," said Paul Offit, director of the Vaccine Education Center at the Children's Hospital of Philadelphia.

The bottom line: The Moderna data may more closely resemble Pfizer's after more time passes. But it may be unwise to use one as a proxy for the other.

  • "It's not clear that any lesson we see from Pfizer will directly translate to Moderna," Dean said. "I think if you asked this question a few months ago, when there really [weren't] any signals of a difference, people would very much lump them together in their mind."

What we're watching: There's a lot more data — particularly from other countries, like Israel — on Pfizer's waning effectiveness, and the effect of booster shots on restoring effectiveness to original levels.

  • But if that data isn't applicable to Moderna, regulators may not yet have much data to work with when making booster decisions — a process that is already highly controversial.
  • "We won't know the real Moderna-specific data for some time now, about restoring effectiveness and how durable that is," said Eric Topol, executive vice president of Scripps Research.
  • Topol said there have been signs Moderna's effectiveness wanes over time to some degree. "It just may be longer and it may be less," Topol added.

Go deeper

19 hours ago - Health

Study: Gaps in data on Native Hawaiians, Pacific Islanders alarming amid COVID

Photo: Patrick T. Fallon/AFP via Getty Images

Native Hawaiians and Pacific Islanders are one of the fastest-growing populations, yet data collection on the community at the federal and state levels remains "virtually nonexistent," according to a new study published in the Journal of Health Politics, Policy, and Law.

Why it matters: In 1997, the Office of Management and Budget mandated the disaggregation of Native Hawaiian and Pacific Islander data from the broader "Asian" category. Yet two decades later, over 30% of federal data sources fail to provide disaggregated NHPI data, a gap that's more pressing than ever due to the pandemic, researchers say.

10 hours ago - Health

COVID cases are falling, but deaths are rising

Data: N.Y. Times; Chart: Kavya Beheraj/Axios

The pace of new coronavirus infections in the U.S. is beginning to slow — a potential sign that the states hit hardest by the Delta wave may be starting to turn things around.

Yes, but: Deaths are still rising, and it’s still too early to know whether schools might drive cases back up again.

Tina Reed, author of Vitals
10 hours ago - Health

Gottlieb: CDC hampered U.S. response to COVID

The CDC moved too slowly at several points in the coronavirus pandemic, ultimately hindering the U.S. response, former FDA Commissioner Scott Gottlieb writes in a new book, Uncontrolled Spread.

The big picture: The book argues that American intelligence agencies should have a much bigger role in pandemic preparedness, even if that's sometimes at the expense of public health agencies like the CDC.